Treatment for diabetic macular oedema: looking further into the evidence

Noemi Lois*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)
30 Downloads (Pure)

Abstract

Throughout the years, people with diabetic macular oedema (DMO) have seen the number of options for their treatment increasing. Laser photocoagulation was the first of these and great experience is behind it; intraocular steroids followed and more recently anti-vascular endothelial growth factor (anti- VEGF) agents came to light. Ophthalmologists face now the dilemma of determining which may be the best therapeutic strategy for each particular patient based on best available evidence. This article summarises data available from randomised clinical trials (RCTs) on treatments for DMO and provides some facts about this condition and its treatments that need to be taken into consideration when treatment decisions are made.

Original languageEnglish
Article number2
JournalAnnals of Eye Science
Volume3
Issue number1
DOIs
Publication statusPublished - 05 Jan 2018

Bibliographical note

Publisher Copyright:
© 2018 AME Publishing Company. All rights reserved.

Keywords

  • Anti-vascular endothelial growth factor (anti-VEGF)
  • Diabetic macular edema (DME)
  • Diabetic macular oedema (DMO)
  • Diabetic retinopathy
  • Laser photocoagulation
  • Randomised clinical trials (RCTs)
  • Retina

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'Treatment for diabetic macular oedema: looking further into the evidence'. Together they form a unique fingerprint.

Cite this